Comparative Analysis of the Two Innovative Vaccines

Abstract

Multiple sclerosis (MS), one of the most prevalent autoimmune diseases, poses a significant challenge for therapeutic advancements. Among these, antigen-specific therapies (ASTs) utilizing therapeutic vaccines have emerged as highly promising. Designed to induce antigen-specific tolerance without compromising the overall immune system, these vaccines offer a glimmer of hope for MS patients, despite many still being in the preclinical trial phase. This research provides an elaborate comparison of two distinct vaccine types: m1Ψ mRNA vaccines and ROS-scavenging CeNP MSN vaccines. As AST vaccines targeting MS, they exhibit notable similarities across various facets, ranging from superficial aspects such as the models employed to evaluate therapeutic effects to deeper considerations like their anti-inflammatory characteristics and key mechanistic factors. Beneath these similarities, significant differences are identified and analyzed within this article. Additionally, the advantages, disadvantages, and noteworthy features of each vaccine are thoroughly compared, accompanied by corresponding suggestions for improvement. Through this comparative analysis of the two innovative vaccines, the paper aims to enhance readers' comprehension of MS treatments. By offering humble insights, it aspires to make a positive impact on related research, ultimately contributing to the advancement of MS therapeutic approaches.